Predicine Secures Over RMB 100 Million in Series B-1 Strategic Financing to Advance Oncology Liquid Biopsy and Global Clinical Trial Solutions
VCBeat (WeChat ID: vcbeat) has learned that Huidu Medical recently announced the completion of its RMB 100 million-plus Series B-1 strategic financing round. The investment was led by Kangjun Capital, with participation from existing shareholders Honghui Capital and Xiantong Capital. The proceeds from this round will primarily be used for global market expansion, team building, and product development.
Founded in 2015, Huidu Medical has successfully developed highly efficient and ultra-sensitive RNA+DNA “Gene Radar” next-generation liquid biopsy technologies and algorithmic models, leveraging the expertise of an elite team from both industry and academia. The company has established a closed-loop genetic testing system and an intelligent medical data platform based on blood, urine, and tumor tissue samples. Huidu Medical operates CLIA- and CAP-accredited laboratories adhering to international standards in both Shanghai and Silicon Valley. It provides global, one-stop, and comprehensive solutions for precise biomarker diagnostics, bioinformatics, and medical big data to pharmaceutical companies worldwide, including seven of the top ten global pharmaceutical firms, supporting their clinical trials.
Huidu Medical also maintains in-depth collaborations with internationally renowned clinical hospitals and academic institutions, and has consecutively published multiple influential academic articles in the field of liquid biopsy in prestigious international journals such as *European Urology*, *EBioMedicine*, and *Breast Cancer Research*.
Addressing critical clinical needs, Huidu Medical leverages its Gene Radar technology and five liquid biopsy products, including TMB, to implement comprehensive, precision oncology management across three domains: new drug clinical trials, personalized medicine, and early cancer screening. Furthermore, the company empowers precision medicine by establishing an intelligent medical big data platform.
Regarding future development plans, Dr. Jia Shidong, Founder, Chairman, and CEO of Huidu Medical, stated, “We extend our sincere gratitude to both new and existing shareholders for their trust and support. The introduction of Kangjun Capital as an industrial strategic investor in this financing round serves as a strong endorsement of Huidu Medical’s business model and development direction. Following this round of financing, we will implement a dual-drive strategy powered by both services and products. Adhering to the principles of being patient-centric and driven by technological innovation, we will further deepen our vertical integration in global new drug clinical trials, tumor recurrence monitoring, and early cancer screening by building and enhancing our smart medical big data platform. We are committed to achieving a comprehensive strategic layout in precision medicine at the earliest possible date.”
Mr. Lou Xiaoqiang, Chairman of Kangjun Capital, stated, “We are deeply honored to participate in Huidu Medical’s precision medicine initiatives! As personalized precision medicine becomes increasingly prevalent in the R&D of novel oncology drugs, the role of biomarker-based precision diagnostics, bioinformatics, and medical big data in new drug clinical trials is growing ever more critical. Huidu Medical has established collaborative partnerships with renowned pharmaceutical companies both in China and abroad, with its technological platform and service quality earning widespread customer recognition. Looking ahead, we hope that Huidu Medical will continue to support a greater number of new drug clinical trials, providing patients with more precise and effective innovative drugs and treatment regimens.”
Bayland Capital is a specialized investment institution in the biomedical sector, jointly established by Pharmaron and Legend Capital. It focuses primarily on global biomedical R&D services and technological innovation platforms. Pharmaron (Stock Codes: 300759.SZ/3759.HK) is an internationally leading life sciences R&D service enterprise with operational entities in China, the United States, and the United Kingdom. With over 8,000 employees, a top-tier talent pool, and high-quality R&D services, Pharmaron has garnered extensive industry recognition and maintains long-term, stable partnerships with pharmaceutical companies and institutions across North America, Europe, Japan, and China. Leveraging Pharmaron’s robust new drug R&D service platform and Legend Capital’s mature investment system, Bayland Capital gains insights into cutting-edge industry technologies and outstanding enterprises through a global industrial perspective. Furthermore, it empowers the rapid growth and development of its portfolio companies by fostering strategic synergies between Pharmaron’s global industrial platform and these investees.
HLC Capital (HLC) is an investment firm focused on the “Healthy Living” sector, dedicated to serving leading enterprises that provide technological products and differentiated services for human disease diagnosis and treatment as well as healthy living. It has conducted in-depth research and practice in the fields of bioengineering, medical devices, diagnostic equipment, personal care, and healthcare. HLC manages dual-currency funds in RMB and USD, with total assets under management exceeding RMB 10 billion. Its portfolio includes high-quality investments such as Mindray Medical, Pharmaron, WuXi AppTec, WuXi Biologics, Yuwell Medical, Borui Medicine, Kintor Pharmaceutical, Sansure Biotech, United Imaging Healthcare, Zentalis Pharmaceuticals, MALO, BEABA, SMOORE, and Nayuki’s Tea.
Xiantong Capital is one of China’s earliest established professional equity investment firms specializing in the biomedical and healthcare sector. Focused on biopharmaceuticals, medical devices, and biotechnology, Xiantong Capital boasts leading professional expertise and a rich project pipeline within the biomedical investment industry. Anchored in the most promising sectors, the firm identifies innovative, high-growth enterprises with substantial capital value and commercial potential, having cultivated a number of benchmark companies in niche markets. With offices in Shenzhen, Beijing, Suzhou, and the United States, Xiantong Capital has assembled an investment and advisory team comprising industry experts, scientists, and investors from the life sciences sector. The firm manages and operates a series of RMB and USD-denominated funds and has received numerous awards and honors from various institutions.